Pricing
Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.
All price changes →Indications & Uses
Rythmosin is indicated for:
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
The dose of Propafenone must be individually titrated on the basis of response and tolerance. It is recommended that therapy be initiated with Propafenone 150 mg given every eight hours (450 mg/day). Dosage may be increased at a minimum of 3 to 4 day intervals to 225 mg every 8 hours (675 mg/day) and if necessary, to 300 mg every 8 hours (900 mg/day). The usefulness and safety of dosages exceeding 900 mg per day have not been established.
Side Effects
Adverse effects most often involve the digestive system, heart and blood vessels, and nervous system. Some people notice a change in taste, constipation, diarrhea, dizziness, drowsiness, a dry mouth, gas, headache, light-headedness, nausea, or tiredness, among other effects. Severe allergic reactions have also been reported with this medicine.
Cautions & Contraindications
Warnings & Precautions
Hepatic Dysfunction: Rythmosin is highly metabolized by the liver and should therefore, be administered cautiously to patients with impaired hepatic function. As a result, the dose of propafenone given to patients with impaired hepatic function should be approximately 20 to 30% of the dose given to patients with normal hepatic function.Renal Dysfunction: A considerable percentage of propafenone metabolites (18.5% to 38% of the dose/48 hours) are excreted in the urine. Until further data are available, propafenone should be administered cautiously to patients with impaired renal function.Neuromuscular Dysfunction: Exacerbation of myasthenia gravis has been reported during propafenone therapy.
Contraindications
Propafenone should not be used in people with uncontrolled congestive heart failure, cardiogenic shock, or disorders of impulse generation and/or conduction in the sinoatrial, atrioventricular, or intraventricular pathways (such as sick sinus node syndrome or atrioventricular block) unless an artificial pacemaker is in place. It is also contraindicated in bradycardia, marked hypotension, bronchospastic disorders, significant electrolyte imbalance, and known hypersensitivity to the drug.